What Is Beovu®?

Beovu® is an injectable treatment that can slow the progression of and treat wet age-related macular degeneration. Brolucizumab, brand named Beovu®, is the newest drug to help treat wet AMD. The FDA approved Beovu® in 2019 as another angiogenesis inhibitor. Beovu® joins Eylea®, Lucentis®, and Macugen® as drugs to help inhibit development of abnormal blood vessels. Another drug, Avastin®, has been approved by the FDA to inhibit blood vessel growth in colorectal and other cancers. It has been used off-label to treat wet AMD.

Frequently Asked Questions

Is Beovu® Safe And What Are The Side Effects?

The most common side effects reported with Beovu® include blurred vision, cataract, broken blood vessels in the eye, vitreous floaters, and eye pain. Rare but serious side effects include eye irritation, eye inflammation, retinal detachment, increased eye pressure, and blood clots in blood vessels.

Skip to content